Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 16, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

December 31, 2026

Conditions
Neuroendocrine Carcinoma of the BladderBladder Cancer
Interventions
DRUG

Adebrelimab

Adebrelimab 1200 mg IV on Day 1, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

DRUG

Etoposide

Etoposide 0.1g IV on Days 1-3, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

DRUG

Cisplatin

Cisplatin 35mg/m2 IV on Days 1-2, once every 3 weeks for up to 4 cycles (each cycle = 21 days)

PROCEDURE

Radical Cystectomy

Radical cystectomy should be performed within 4-6 weeks after completion of last dose

Trial Locations (1)

200127

RECRUITING

Ren Ji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER